Prognosis and primary therapy in peripheral T-cell lymphomas

Area of Science:

• Hematology
• Oncology

Background:

• Peripheral T-cell lymphomas (PTCLs) are uncommon neoplasms with significant racial and geographic variations.
• Prognostic factors for PTCLs are increasingly understood through modern lymphoma classifications.
• PTCLs exhibit diverse clinical behaviors, ranging from favorable prognoses (e.g., ALK-positive anaplastic large-cell lymphoma) to aggressive, fatal courses (e.g., hepatosplenic gammadelta T-cell lymphomas).

Purpose of the Study:

• To highlight the challenges in diagnosing and treating PTCLs due to their rarity and heterogeneity.
• To underscore the relative chemoresistance of most PTCLs to standard regimens like CHOP chemotherapy, contrasting with diffuse large B-cell lymphoma.
• To emphasize the recent emergence of studies focused on PTCLs to advance understanding of disease biology and therapeutic strategies.

Main Methods:

• Review of recent studies and modern lymphoma classification systems.
• Analysis of prognostic significance of T-cell phenotypes.
• Comparison of treatment responses to standard chemotherapy regimens.

Main Results:

• Peripheral NK/T-cell neoplasms demonstrate significant heterogeneity in prognosis and treatment response.
• ALK-positive anaplastic large-cell lymphoma and primary cutaneous ALCL show more favorable prognoses.
• Most PTCLs, excluding ALK-positive ALCL, exhibit relative chemoresistance to CHOP chemotherapy.

Conclusions:

• Advances in PTCL diagnosis, prognosis, and treatment have historically lagged behind other lymphomas like DLBCL.
• There is a growing focus on PTCL-specific research to improve patient outcomes.
• Further investigation into PTCL biology is crucial for developing more effective therapies.